April 2009

Localized Contact Urticaria Caused by Lidocaine/Tetracaine Peel

Author Affiliations

Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009

Arch Dermatol. 2009;145(4):499-500. doi:10.1001/archdermatol.2009.56

The lidocaine, 7%/tetracaine, 7%, cream Pliaglis (Galderma Laboratories, Fort Worth, Texas) (hereinafter, “LT peel”) is a novel topical anesthetic cream that forms a self-occlusive, pliable membrane on exposure to air. The LT peel has been shown to be a safe and effective form of local anesthesia for various dermatologic procedures.1 Minimal adverse effects associated with the LT peel have been reported, limited primarily to transient skin erythema with or without skin discoloration or edema.1 Herein, we report a case of contact urticaria and discuss possible causes of such allergic manifestations and potential hazards and precautions recommended with the use of the LT peel.

First Page Preview View Large
First page PDF preview
First page PDF preview